Mercer Capital Advisers’s Biogen BIIB Stock Holding History

Mercer Capital Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$453K	Sell	1,600 -500	-24%	-$164K	0.24%	62
2021 Q2	$727K	Buy	2,100 +1,500	+250%	+$454K	0.36%	50
2021 Q1	$168K	Hold	600	–	–	0.09%	108
2020 Q4	$147K	Sell	600 -175	-23%	-$45.1K	0.08%	106
2020 Q3	$220K	Hold	775	–	–	0.14%	78
2020 Q2	$207K	Hold	775	–	–	0.13%	84
2020 Q1	$245K	Buy	+775	New	+$235K	0.18%	69

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mercer Capital Advisers's BIIB Position: Q3 2021 in Review

Mercer Capital Advisers reduced its Biogen (BIIB) stake by 24% in Q3 2021, selling an estimated $164K and leaving 1,600 shares worth $453K. The position accounts for 0.24% of the portfolio, ranked #62.

Mercer Capital Advisers first reported a position in BIIB in Q1 2020 and has held it in 7 quarters since. The position peaked at $727K in Q2 2021. 1,039 funds tracked by Wall St. Rank hold BIIB as of Q3 2021.

Mercer Capital Advisers held 1,600 shares of Biogen worth $453K as of Q3 2021.
Mercer Capital Advisers sold 500 Biogen shares in Q3 2021, an estimated $164K.
Biogen made up 0.24% of Mercer Capital Advisers's portfolio in Q3 2021, its #62 holding.
Mercer Capital Advisers first reported a position in Biogen in Q1 2020 and has held it in 7 quarters since.
Mercer Capital Advisers's Biogen position peaked at $727K in Q2 2021.
1,039 funds tracked by Wall St. Rank held Biogen as of Q3 2021.

Based on Mercer Capital Advisers's 13F filing for Q3 2021, filed 27 Oct 2021.